financetom
Business
financetom
/
Business
/
Outbrain to Expand Operations With Microsoft Azure in North America
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Outbrain to Expand Operations With Microsoft Azure in North America
Nov 3, 2024 3:49 PM

11:18 AM EDT, 10/31/2024 (MT Newswires) -- Outbrain ( OB ) said Thursday it will expand its operations with Microsoft's ( MSFT ) Azure cloud platform in North America as part of its expanded collaboration with the tech giant.

Outbrain ( OB ) said it will use Azure's technological capabilities to enhance its offerings for advertisers and media owners.

Outbrain ( OB ) Chief Technology Officer Yonatan Maman said the company is transferring another data center and strengthening its existing partnership with Microsoft ( MSFT ) about two years following the initial move to Azure.

Outbrain ( OB ) shares were down 1.6% while Microsoft ( MSFT ) shares were falling 5.9% in recent Thursday trading.

Price: 4.30, Change: -0.07, Percent Change: -1.60

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Dominion Energy Keeps Quarterly Dividend at $0.6675 per Share, Payable Dec. 20 to Holders of Record Nov. 29
--Dominion Energy Keeps Quarterly Dividend at $0.6675 per Share, Payable Dec. 20 to Holders of Record Nov. 29
Nov 3, 2024
03:17 PM EDT, 10/31/2024 (MT Newswires) -- Price: 59.73, Change: +1.28, Percent Change: +2.18 ...
Biogen, Eisai Submit Biologics License Application for Alzheimer's Subcutaneous Autoinjector to US FDA
Biogen, Eisai Submit Biologics License Application for Alzheimer's Subcutaneous Autoinjector to US FDA
Nov 3, 2024
08:13 AM EDT, 11/01/2024 (MT Newswires) -- Biogen (BIIB) and Eisai said late Thursday that Eisai finalized a biologics license application rolling submission to the FDA for a subcutaneous autoinjector of LEQEMBI, or lecanemab-irmb, for weekly dosing in early-stage Alzheimer's disease. The device, which is designed for home or clinic use, allows a 15-second injection and supports sustained drug levels...
Mobileye Shares Rise After Q3 Revenue Beats Estimates; 2024 Guidance Narrowed
Mobileye Shares Rise After Q3 Revenue Beats Estimates; 2024 Guidance Narrowed
Nov 3, 2024
11:19 AM EDT, 10/31/2024 (MT Newswires) -- Mobileye Global ( MBLY ) shares were more than 4% higher in recent Thursday trading after the company's Q3 revenue beat analyst estimates. The company reported Q3 adjusted earnings of $0.10 per diluted share, compared with $0.22 a year earlier. Analysts surveyed by Capital IQ expected $0.10 per share. Revenue for the quarter...
Cboe beats third-quarter profit estimates on strong hedging activity
Cboe beats third-quarter profit estimates on strong hedging activity
Nov 3, 2024
Nov 1 (Reuters) - Cboe Global Markets ( CBOE ) beat estimates for third-quarter profit on Friday, helped by strong options trading as investors actively hedged against geopolitical and economic uncertainties. A robust equities market, shifts in the U.S. Federal Reserve's key policy rates and the potential economic fallout from the Middle East conflict have investors and portfolio managers on...
Copyright 2023-2026 - www.financetom.com All Rights Reserved